We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+21.28%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.03B
AUM Growth
+$384M
Cap. Flow
+$76.6M
Cap. Flow %
3.78%
Top 10 Hldgs %
49.69%
Holding
79
New
15
Increased
27
Reduced
15
Closed
14

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$71M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$60.3M
3
ALDR
Alder Biopharmaceuticals
ALDR
+$44.3M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$38.2M
5
INSM icon
Insmed
INSM
+$37.7M

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$66.3M
2
ELV icon
Elevance Health
ELV
+$43.6M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$35M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$32M
5
PEN icon
Penumbra
PEN
+$31.5M

Sector Composition

Rank Sector Weight
1 Healthcare 94.27%
2 Financials 3.41%
3 Miscellaneous 1.69%
4 Communication Services 0.62%
5 Energy 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTLT
51
DELISTED
CATALENT, INC.
CTLT
$5.89M 0.29%
147,663
+1,700
+1% +$63K
FATE icon
52
Fate Therapeutics
FATE
$291M
$5.62M 0.28%
1,419,058
– –
OVID icon
53
Ovid Therapeutics
OVID
$547M
$3.77M 0.19%
451,182
+2,401
+0.5% +$20K
NDRM
54
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$2.98M 0.15%
76,729
-478,367
-86% -$17.6M
ACRS icon
55
Aclaris Therapeutics
ACRS
$885M
$2.61M 0.13%
100,960
+6,400
+7% +$172K
AUPH icon
56
Aurinia Pharmaceuticals
AUPH
$2.17B
$2.08M 0.1%
332,310
– –
HOLX
57
DELISTED
Hologic
HOLX
$734K 0.04%
+20,000
New +$807K
NBIX icon
58
Neurocrine Biosciences
NBIX
$15.7B
$407K 0.02%
6,640
– –
UNH icon
59
UnitedHealth
UNH
$353B
$356K 0.02%
1,820
– –
NKTR icon
60
Nektar Therapeutics
NKTR
$2.48B
$350K 0.02%
972
– –
LHCG
61
DELISTED
LHC Group LLC
LHCG
$235K 0.01%
+3,310
New +$212K
SHPG
62
DELISTED
Shire pic
SHPG
$208K 0.01%
+1,360
New +$213K
ADVM
63
DELISTED
Adverum Biotechnologies
ADVM
$81K ﹤0.01%
2,224
– –
CSLT
64
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$44K ﹤0.01%
10,229
– –
AGIO icon
65
Agios Pharmaceuticals
AGIO
$1.99B
– –
-681,165
Closed -$35M
BKD icon
66
Brookdale Senior Living
BKD
$2.8B
– –
-12,110
Closed -$178K
BPMC
67
DELISTED
Blueprint Medicines
BPMC
– –
-367,537
Closed -$18.6M
ELV icon
68
Elevance Health
ELV
$85.5B
– –
-231,886
Closed -$43.6M
EW icon
69
Edwards Lifesciences
EW
$52B
– –
-654,000
Closed -$25.8M
PBYI icon
70
CALL
Puma Biotechnology
PBYI
$468M
– –
-101,500
Closed -$8.87M
PRTA icon
71
Prothena Corp
PRTA
$479M
– –
-509,698
Closed -$27.6M
NSTG
72
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-866,819
Closed -$14.3M
CLVS
73
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-152,000
Closed -$14.2M
GBT
74
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-631,283
Closed -$17.3M
AGN
75
DELISTED
Allergan plc
AGN
– –
-1,200
Closed -$292K
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2017 Portfolio in Review

As of Q3 2017, Redmile Group held 79 positions worth $2.03B, up 23% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Redmile Group deployed $76.6M of net new capital in Q3 2017, opening 15 new positions and adding to 27 existing holdings. Its largest new stake was AstraZeneca: 1,123,150 shares worth $76.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Syneos Health, Inc. Class A Common Stock, an estimated $32M trimmed.

  • Redmile Group's largest Q3 2017 buy was AstraZeneca: 1,123,150 shares worth $76.1M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q3 2017, an estimated $60.3M increase.
  • Redmile Group's biggest Q3 2017 reduction was Syneos Health, Inc. Class A Common Stock, cutting an estimated $32M.
  • Redmile Group fully exited Juno Therapeutics, Inc. in Q3 2017, selling an estimated $66.3M.
  • Redmile Group's ten largest holdings make up 50% of its $2.03B portfolio in Q3 2017.
  • Redmile Group opened 15 new positions and closed 14 in Q3 2017.
  • Redmile Group's portfolio value rose 23% quarter-over-quarter to $2.03B.

Based on Redmile Group's 13F filing for Q3 2017, filed 14 Nov 2017.